Clinical evidence for the use of ARB in CRS-4 is perhaps provided by the UK HARP-III trial which demonstrated that ARB administration in patients with CKD reduced troponin and N-terminal prohormone of brain natriuretic peptide (NTproBNP) levels over 12 months [66]. This evidence concerns the gene NPPB and chronic kidney disease.